Dominari (DOMH) & Its Competitors Head to Head Contrast

Dominari (NASDAQ:DOMHGet Rating) is one of 44 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its rivals? We will compare Dominari to similar companies based on the strength of its risk, analyst recommendations, dividends, earnings, valuation, profitability and institutional ownership.

Volatility & Risk

Dominari has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, Dominari’s rivals have a beta of 4.90, suggesting that their average share price is 390% more volatile than the S&P 500.

Insider & Institutional Ownership

10.9% of Dominari shares are held by institutional investors. Comparatively, 56.5% of shares of all “Commercial physical research” companies are held by institutional investors. 8.6% of Dominari shares are held by company insiders. Comparatively, 12.5% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Dominari and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dominari N/A -18.21% -16.94%
Dominari Competitors -244.63% -12.67% -6.96%

Analyst Ratings

This is a summary of recent ratings for Dominari and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dominari 0 0 0 0 N/A
Dominari Competitors 44 680 1259 25 2.63

As a group, “Commercial physical research” companies have a potential upside of 18.08%. Given Dominari’s rivals higher possible upside, analysts clearly believe Dominari has less favorable growth aspects than its rivals.

Valuation & Earnings

This table compares Dominari and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Dominari N/A -$7.17 million -1.02
Dominari Competitors $1.53 billion $80.65 million -14.31

Dominari’s rivals have higher revenue and earnings than Dominari. Dominari is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Dominari rivals beat Dominari on 8 of the 9 factors compared.

Dominari Company Profile

(Get Rating)

Dominari Holdings, Inc. is a biotechnology development company, which engages in the provision of diversified portfolio of small-molecule anticancer and antiviral therapeutics in development. Its oncology therapeutics includes treatments for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia. It also creates a broad-spectrum antiviral platform, in which the lead compounds have activity against multiple viruses including Influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2, the cause of COVID-19. The company was founded by Gilbert V. Levin and M. Karen Levin in 1967 and is headquartered in New York, NY.

Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.